SCHEDULE: Intracoastal Capital Discloses 4.99% Stake in Cellectar Biosciences
Beneficial Ownership Disclosure
Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a beneficial ownership of 4.99% in Cellectar Biosciences, Inc. common stock as of July 8, 2025.
Summary
- Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have filed a Schedule 13G disclosing their beneficial ownership in Cellectar Biosciences, Inc.
- As of July 8, 2025, each Reporting Person is deemed to have beneficial ownership of 140,101 shares of Cellectar Biosciences, Inc. common stock.
- This beneficial ownership represents approximately 4.99% of the common stock outstanding.
- The 140,101 shares consist of 9,500 shares directly held by Intracoastal Capital LLC and 130,601 shares issuable upon the exercise of the Intracoastal Warrant.
- The Intracoastal Warrant includes a blocker provision preventing exercise to the extent that it would result in beneficial ownership exceeding 4.99% of the common stock.
- Immediately following the underwritten public offering by Cellectar Biosciences on July 1, 2025, the Reporting Persons may have been deemed to beneficially own 150,000 shares, representing approximately 5.6% of the common stock, before accounting for the blocker provision.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or prospects.
Positives
- NA
Negatives
- NA
Risks
- The beneficial ownership percentage is capped at 4.99% due to a blocker provision in the Intracoastal Warrant, which limits the ability of the holder to exercise the warrant if it would result in ownership exceeding this threshold.
Future Outlook
NA
Management Comments
- NA
Industry Context
NA
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding significant ownership stakes by institutional investors and individuals, which can influence market perception and trading activity.
- Management: Awareness of significant shareholder positions can influence strategic decisions and investor relations.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2025-07-01 | Date of event which requires filing of this statement; consummation of the underwritten public offering by Cellectar Biosciences, Inc. |
| 2025-07-02 | Date of Form 424B4 prospectus filing by Cellectar Biosciences, Inc. with the SEC. |
| 2025-07-08 | Date of filing of the Schedule 13G; close of business date for beneficial ownership calculation. |
Keywords
Cellectar Biosciences, Intracoastal Capital, Mitchell P. Kopin, Daniel B. Asher, Schedule 13G, beneficial ownership, common stock, warrant, equity stake, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.